Compare LZB & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZB | ABCL |
|---|---|---|
| Founded | 1927 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1994 | 2020 |
| Metric | LZB | ABCL |
|---|---|---|
| Price | $39.63 | $7.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $39.00 | $8.40 |
| AVG Volume (30 Days) | 743.9K | ★ 7.1M |
| Earning Date | 06-16-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | 5.11 | ★ 10.91 |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $2,349,433,000.00 | $75,128,000.00 |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $2.09 | $21.85 |
| P/E Ratio | $16.24 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $29.03 | $2.75 |
| 52 Week High | $44.90 | $8.42 |
| Indicator | LZB | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 55.66 | 72.41 |
| Support Level | $36.31 | $3.32 |
| Resistance Level | $39.76 | N/A |
| Average True Range (ATR) | 1.73 | 0.54 |
| MACD | -0.01 | 0.24 |
| Stochastic Oscillator | 46.29 | 82.11 |
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.